Taking people in BelgiumPhase 1
Testing an ERAP-inhibition drug in people with axial spondyloarthritis
Tests an ERAP-inhibition drug in adults with axial spondyloarthritis, a form of arthritis.
Key facts
- Who runs it
- Grey Wolf Therapeutics Limited
- Where
- Gent and Leuven, BelgiumSee the 2 sitesAlso in 4 other countries, 7 sites
- Trial code
- Registry title
- EAST-1 (ERAP-inhibition in Axial Spondyloarthritis Trial-1)
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 86 people, planned
- Started
- 5 Nov 2025
- Expected to end
- 31 Dec 2028
- Type of study
- Interventional
- Record updated
- 6 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with axial spondyloarthritis. The record gives no further details.
- Age
- 18 years or older
- Sex
- All sexes can join
Where in Belgium
Also in 4 other countries, 7 sites
- Universitair Ziekenhuis GentGent, BelgiumTaking people
- UZ LeuvenLeuven, BelgiumTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Plain-language title
- Testing an ERAP-inhibition drug in people with axial spondyloarthritisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 6 October 2026